On May 20, 2020, Assertio Holdings completed the previously announced merger pursuant the Agreement and Plan of Merger (the Merger Agreement") by and between Assertio Therapeutics, Inc., a Delaware corporation (Assertio), Zyla Life Sciences, a Delaware corporation (Zyla), Assertio Holdings (formerly known as Alligator Zebra Holdings, Inc.), Alligator Merger Sub, Inc., a Delaware corporation (Assertio Merger Sub), and Zebra Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (Merger Sub). Pursuant to the Merger Agreement, Zebra Merger Sub merged with and into Zyla on May 20, 2020 effective as of the filing of the certificate of merger with the Delaware Secretary of State (the Effective Time"), with Zyla continuing as the surviving corporation and wholly-owned subsidiary of Assertio Holdings (the Merger). In connection with the consummation of the Merger, Karen A. Dawes, James P. Fogarty and James J. Galeota, Jr. resigned from the board of the Company effective as of May 19, 2020.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
ASSERTIO HOLDINGS, INC. 
